SVB Wealth LLC Decreases Stock Position in 10x Genomics $TXG

Key Points

• SVB Wealth LLC reduced its stake in 10x Genomics by 17.9%, now holding 0.35% of the company, valued at approximately $3.75 million.
• Numerous institutional investors have modified their positions, with GAMMA Investing LLC increasing its holdings by 81.8% in the first quarter.
• Analysts have set a range of price targets for 10x Genomics, with current average ratings showing six "Buy," six "Hold," and one "Sell" rating.

SVB Wealth LLC lowered its holdings in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 17.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 429,117 shares of the company's stock after selling 93,492 shares during the quarter. SVB Wealth LLC owned approximately 0.35% of 10x Genomics worth $3,746,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after acquiring an additional 1,614 shares during the last quarter. Invesco Ltd. increased its holdings in shares of 10x Genomics by 21.8% in the fourth quarter. Invesco Ltd. now owns 118,067 shares of the company's stock valued at $1,695,000 after purchasing an additional 21,134 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of 10x Genomics by 35.3% in the fourth quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock valued at $146,000 after purchasing an additional 2,657 shares during the last quarter. Cetera Investment Advisers increased its holdings in shares of 10x Genomics by 22.7% in the fourth quarter. Cetera Investment Advisers now owns 19,898 shares of the company's stock valued at $286,000 after purchasing an additional 3,679 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of 10x Genomics by 11.4% in the first quarter. Rhumbline Advisers now owns 120,490 shares of the company's stock valued at $1,052,000 after purchasing an additional 12,374 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Bank of America increased their price target on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Thursday, June 26th. Wall Street Zen raised 10x Genomics from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. UBS Group increased their price target on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, August 8th. The Goldman Sachs Group cut their price target on 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a report on Monday, May 12th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price target on 10x Genomics and gave the company a "hold" rating in a report on Friday, August 8th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, 10x Genomics presently has a consensus rating of "Hold" and an average price target of $13.54.

Insider Activity

In other news, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares of the company's stock, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the sale, the insider directly owned 440,888 shares of the company's stock, valued at $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,149 shares of company stock valued at $539,865. 9.39% of the stock is currently owned by corporate insiders.

10x Genomics Stock Performance

Shares of NASDAQ TXG traded up $0.26 during trading on Thursday, reaching $14.28. The stock had a trading volume of 1,042,818 shares, compared to its average volume of 3,383,684. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.76. The business's 50-day moving average price is $12.79 and its 200-day moving average price is $10.67. The company has a market cap of $1.78 billion, a P/E ratio of -20.31 and a beta of 2.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business had revenue of $172.91 million during the quarter, compared to analysts' expectations of $139.36 million. During the same period in the previous year, the firm posted ($0.32) earnings per share. The company's revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. Analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.